These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 25503330)

  • 21. Market watch: Upcoming market catalysts in Q3 2017.
    Nghiem S
    Nat Rev Drug Discov; 2017 Jul; 16(7):449. PubMed ID: 28620177
    [No Abstract]   [Full Text] [Related]  

  • 22. Market watch: Upcoming catalysts in Q4 2014.
    Ang A
    Nat Rev Drug Discov; 2014 Oct; 13(10):716. PubMed ID: 25233996
    [No Abstract]   [Full Text] [Related]  

  • 23. Market watch: industry perspectives on personalized medicine.
    Zuckerman R; Milne CP
    Nat Rev Drug Discov; 2012 Mar; 11(3):178. PubMed ID: 22378258
    [No Abstract]   [Full Text] [Related]  

  • 24. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates.
    Berndt ER; Gottschalk AH; Philipson TJ; Strobeck MW
    Nat Rev Drug Discov; 2005 Jul; 4(7):545-54. PubMed ID: 16052239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Market watch: upcoming market catalysts in Q3 2012.
    Jeng R
    Nat Rev Drug Discov; 2012 Jun; 11(7):508. PubMed ID: 22743969
    [No Abstract]   [Full Text] [Related]  

  • 26. Market watch: Upcoming market catalysts in Q1 2017.
    Fulton Z
    Nat Rev Drug Discov; 2016 Dec; 16(1):11. PubMed ID: 28031567
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA dependence on drug industry.
    Lawson GW
    J Natl Med Assoc; 2005 Jul; 97(7):1039-40. PubMed ID: 16080677
    [No Abstract]   [Full Text] [Related]  

  • 28. Paying for drug approvals--who's using whom?
    Avorn J
    N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract]   [Full Text] [Related]  

  • 29. User fees for faster drug reviews. Are they helping or hurting the public health?
    Thompson L
    FDA Consum; 2000; 34(5):25-9. PubMed ID: 11590789
    [No Abstract]   [Full Text] [Related]  

  • 30. Market watch: Upcoming market catalysts in Q2 2017.
    Ho E
    Nat Rev Drug Discov; 2017 Apr; 16(4):231. PubMed ID: 28303023
    [No Abstract]   [Full Text] [Related]  

  • 31. Upcoming market catalysts in Q4 2009.
    Jatkoe L
    Nat Rev Drug Discov; 2009 Oct; 8(10):763. PubMed ID: 19794437
    [No Abstract]   [Full Text] [Related]  

  • 32. Variations in time of market exclusivity among top-selling prescription drugs in the United States.
    Wang B; Liu J; Kesselheim AS
    JAMA Intern Med; 2015 Apr; 175(4):635-7. PubMed ID: 25664700
    [No Abstract]   [Full Text] [Related]  

  • 33. New fee structure proposed by FDA might lead to more talk.
    Waters H
    Nat Med; 2011 Oct; 17(10):1159. PubMed ID: 21988966
    [No Abstract]   [Full Text] [Related]  

  • 34. User fees to hasten FDA review.
    Gershon D
    Nature; 1992 Oct; 359(6396):567. PubMed ID: 1406982
    [No Abstract]   [Full Text] [Related]  

  • 35. Market exclusivity for top-selling pharmaceuticals: too long, too short, or just right?
    Downing NS
    JAMA Intern Med; 2015 Apr; 175(4):637-8. PubMed ID: 25664529
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 37. PDUFA reauthorization--drug safety's golden moment of opportunity?
    Hennessy S; Strom BL
    N Engl J Med; 2007 Apr; 356(17):1703-4. PubMed ID: 17435082
    [No Abstract]   [Full Text] [Related]  

  • 38. Market watch: Upcoming market catalysts in Q1 2014.
    Stopke E
    Nat Rev Drug Discov; 2014 Jan; 13(1):11. PubMed ID: 24378790
    [No Abstract]   [Full Text] [Related]  

  • 39. Current and future state of FDA-CMS parallel reviews.
    Messner DA; Tunis SR
    Clin Pharmacol Ther; 2012 Mar; 91(3):383-5. PubMed ID: 22343814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA starts moving on critical path, but initiative running out of steam.
    Finkelstein JB
    J Natl Cancer Inst; 2007 Mar; 99(6):426-7. PubMed ID: 17374831
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.